Is Jazz Pharmaceuticals Stock A Real Bargain?

For questions about this article or underlying research, email help@trefis.com.

Jazz Pharmaceuticals (JAZZ) stock currently trades at 13.8 times earnings, compared to a 23.0 multiple for the median S&P 500 company. The shares have lost 19.9% since July 28, 2026, while the S&P 500 gained 3.6%. A buyer can interpret that price in two ways: either a sound drug business is on sale, or it is a fair price for profits that have not lasted before. So what does that price actually buy?

What Jazz Pharmaceuticals Buyers Get At Today’s Price

A buyer at today’s price acquires a drug company that is growing faster and keeping more of each sales dollar than the median S&P 500 company. Jazz’s revenue rose 12.6% over the four quarters to June 30, 2026, compared with 8.4% for the median company. Its operating margin over those quarters reached 22.1%, against 18.5%.

Multiple drugs are driving that growth. On an August 3 call, management said the company’s cancer drugs grew 32% in the second quarter of 2026, and that Epidiolex, an epilepsy drug, grew 16%. In the same quarter, the sleep drug Xywav added about 525 net patients.

Jazz also generated $1.31 billion of free cash flow over those four quarters. That figure represents about a tenth of its $13.0 billion market value at the October 26 close.

Jazz Pharmaceuticals Has Swung Between Profit And Loss

In the twelve months to June of each year from 2021 to 2026, Jazz reported a net loss in three of the six periods. Today’s P/E is measured on the $941 million Jazz earned in the latest four quarters, which followed a loss of $405 million in the twelve months before. That is the largest profit of the six periods. The next best was $395 million, recorded in the twelve months to June 2024.

Jazz’s own average sits well below its latest year. Across the three twelve-month periods to June 2024, 2025 and 2026, revenue growth averaged 7.0%, compared with 12.6% in the latest period. The operating margin averaged 17.4% over those periods, below the latest 22.1%.

Total revenue grew 15.5% in the second quarter of 2026, against 2.1% a year earlier, and an easy comparison outside the US accounted for some of that increase. Management said on the August 3 call that one-time pricing adjustments in a couple of markets there had held down revenue in the second quarter of 2025. Management also expects the older second-line business of Zepzelca, a cancer drug, to erode. They said on the call that their plan to ask the FDA to remove that use from the label may speed that up.

How Jazz Pharmaceuticals Plans To Keep Growing

Jazz is launching and buying new drugs. On August 25, 2026, the FDA approved Ziihera for a new use: first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The drug was already on sale for an earlier use, and Ziihera sold $15 million in the second quarter. To expand its rare epilepsy drugs, Jazz also agreed to buy Actio Biosciences for $820 million, according to news reports on August 11, 2026.

Jazz has also borrowed more, selling $1.1 billion of exchangeable notes due 2032 on August 27, 2026. Even before those notes, its debt at June 30, 2026, equaled 33.9% of its market value at the October 26 close, against 19.4% for the S&P 500 taken as a whole.

Management’s own bar is its 2026 revenue forecast, which was raised on August 3 to a midpoint of $4.68 billion, from $4.38 billion. The same August 3 earnings release raised the forecast for selling and administrative costs to a midpoint of $1.53 billion, from $1.46 billion, so the company expects to spend more to reach the higher sales.

A buyer at this price is betting that Jazz’s latest twelve months of profit represent a new base built on Xywav, Epidiolex and the cancer drugs, rather than another high point in a record that has swung between profit and loss. Jazz’s net income for the third quarter of 2026, in the report expected in November 2026, is the figure to watch.

Does This Mean You Should Act On JAZZ?

Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.

There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.

Spot an error or want more like this? Tell us in 10 seconds.